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Summary Mycobacterium tuberculosis (Mtb) and the human immunodeficiency virus (HIV) are
both life-threatening pathogens in their own right, but their synergic effects on the immune
system during co-infection markedly enhance their effect on the host. This review focuses on the
bidirectional interaction between HIV and Mtb and discusses the relevance of sputum smear
examination, CD4+ counts, viral load at baseline and after initiation of anti-retroviral therapy, as
well as additional existing and new potential immune correlates of disease progression and
prognosis. These markers include b2-microglobulin, neopterin, tumor necrosis factor receptor II
(TNFRII), CD8+/CD38+, soluble urokinase plasminogen activator receptor (suPAR) and CXCL10 (or
IP-10).
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infection
The influence of concurrent human immunodeficiency virus
(HIV) and Mycobacterium tuberculosis (Mtb) infection on dis-
ease progression of both individual diseases has been clearly
established during the past years.Mtb infection represents the
leading cause ofmortality in HIV-infected patients,1,2 whereas
HIV is a very strong factor predisposing Mtb-infected subjects* Corresponding author. Tel.: +27 21 9389399; fax: +27 21 9389476.
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doi:10.1016/j.ijid.2007.02.001to reactivation and progression to active tuberculosis (TB).3,4
For example, the lifetime risk of progressing to active TB in
people with latent infection with Mtb (LTBI) is about 5%.5 This
escalates to well over 10%2,4 with an annual rate between 7%
and 10%,when there is concurrentHIV infection.6 Additionally,
the risk ofmortality due to concurrent HIV/Mtb is twice that of
HIV infection alone.7
Interference with the ability of dendritic cells to
direct the adaptive immune response
Key concepts in the immunologic interplay of Mtb and HIV
infection are summarized in Figure 1. LTBI is a dynamic statePublished by Elsevier Ltd. All rights reserved.
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Figure 1 Key concepts of immunopathogenesis of latent TB. In brief, cytokines drive the interaction between CD4+ T-cells and
infectedmacrophages. Stable latent TB infection requires dominance of Th1 over Th2 for effective containment of the infection within
granulomas. HIV infection results in T-cell depletion but also in a switch from Th1 to Th2 dominance, thus enabling progression to active
disease. The uptake of HIV through DC-SIGN enables transinfection of CD4+ T-cells and leads to both functional defects and loss of CD4+
cells that are required for an effective immune response against Mtb. DC, dendritic cell; IL, interleukin; IFN, interferon; TNF, tumor
necrosis factor; Th, T helper cell; Treg, regulatory T-cell; TGF, transforming growth factor; DC-SIGN, DC-specific intercellular adhesion
molecule-3-grabbing nonintegrin; Mtb, Mycobacterium tuberculosis.betweenmycobacterium and host immunity. Infected macro-
phages and dendritic cells (DCs) process and present myco-
bacterial and viral antigens to CD4+ and CD8+ T-cells and
other lymphocyte subsets like regulatory T-cells, gd and
natural killer (NK) cells. Processed peptides together with
macrophage/DC-derived interleukin (IL)-12 favor T helper
cell 1 (Th1) differentiation and secretion of interferon- g
(IFN-g), IL-2 and tumor necrosis factor-a (TNF-a), which are
believed to be protective.8 Although DCs are seen as crucial
in the production of an effective adaptive immune response
due to their ability to carry antigens to lymphoid tissue where
interactions with CD4+ T-cells occur,9,10 it has been reported
that DC-specific intercellular adhesion molecule-3-grabbingnonintegrin (DC-SIGN)-dependent uptake of HIV facilitates T-
cell transinfection.11—13 Mycobacteria also shed molecules
interacting with DCs and macrophages through DC-SIGN and
this has been shown to stimulate secretion of the anti-inflam-
matory cytokine IL-10, thereby suppressing DC function and
maturation.14 This could have severe consequences in the case
of concurrentHIVandMtb infection as the conjugatedeffect of
the two pathogens will supposedly increase not only DC-
dependent T-cell transinfection but also minimize the ability
of the host to respond adequately to pathogens, thereby
enhancing their survival and dissemination.
Substantial evidence exists that DCs can influence the
immune response and outcome of infections although the
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have been described in humans and include the following: the
myeloid DCs (DC1) that elicit the Th1 response in the pre-
sence of IL-12, and the plasmacytoid DCs (DC2) that elicit a
Th2 response when IL-4 is present.15 It has been shown that
the presence of IL-10 and the absence of IL-12 may lead to
Th2 polarization by default.16 This may be one of the means
by which Mtb-infected DCs shift the Th-cell balance from the
required Th1 response to a more deleterious Th2 type
response.
Cytokine dysregulation drives immunopathology
during concurrent HIV and Mtb infection
TNF-a and IFN-g are key cytokines in granuloma formation
that contain TB infection; however, pro-inflammatory cyto-
kines and especially TNF-a will, in excess, lead to severe
tissue destruction and caseating necrosis.17 The sustained
containment of stable LTBI is based on the balance between
protective responses (pro-inflammatory) and suppressive
responses (anti-inflammatory) to limit immunopathology.
The dominant Th1 cell activation is under the regulation
of other T-cell subsets. Polarized Th2 sets secrete IL-4, IL-
10 and IL-13 and thereby inhibit the Th1-mediated pro-
inflammatory and tissue-destructive response. CD4+CD25+
regulatory T-cells favor Th2 skewing by augmenting suppres-
sive reactions and promoting negative feedback on Th1
cells.18 Secretion of IL-4 in active TB patients has always
been looked at as an indicator of Th2 cell activity.19 There is
evidence that increased IL-4 secretion enhances TNF-a toxi-
city and fibrosis20 and promotes TNF-a-mediated apoptosis in
Mtb activated lymphocytes. IL-4 is therefore involved in the
immunopathology of TB infection21 and its presence has been
associated with the extent of tuberculosis disease.22—24
In the case of concurrent HIV and Mtb infection the IL-4/
TNF-a interaction could exacerbate the situation, as the
depletion of T-cells would make the host vulnerable to HIV
progression. The discovery of IL-4d2, an IL-4 splice variant
and IL-4 antagonist, has brought new insight into the concept
of immune regulation and problems with its assessment.
Commonly used immunoassays for IL-4 do not differentiate
between IL-4 and its splice variant, and it is now clear that IL-
4 levels have to be interpreted together with IL-4d2 expres-
sion levels. Recent studies have shown increased expression
of IL-4d2 in individuals with LTBI, unlike active TB patients
who have low expression of IL-4d2 and increased IL-4 expres-
sion.24,25 It has also been reported that TB patients have
greater levels of mRNA for both cytokines when compared to
healthy controls, and that only IL-4d2 levels increase in
parallel with IFN-g after anti-TB treatment.23
Investigations of concurrent HIV and Mtb infections have
led to the concept that Mtb-induced T-cell turnover speeds
up the progression of asymptomatic HIV infection to AIDS by
triggering viral replication26,27 and inducing programmed cell
death in T-lymphocytes through TNF-a-dependent path-
ways.27,28 The subsequent increase in viral load leads to
altered immune cell function,29,30 further T-cell infection
and depletion.31 The subsequent weakening of cellular
immunity and loss of pro-inflammatory cytokine production
leads to granuloma disintegration,32 or the inability to form
granulomas,33 and ultimately to HIV-associated active TB and
even death.31,34 In individuals with LTBI the progressivedepletion of CD4+ T-cells caused by HIV activity increases
the likelihood of Mtb reactivation and disease.35 HIV infection
has also been shown to negatively impact on TB recurrence
and treatment failure.36,37 It is the underlying cause of the
paradoxical reaction38,39 and presumed to increase the like-
lihood for developing TB drug resistance.40
Tuberculosis immune reconstitution
inflammatory syndrome (TB IRIS)
TB IRIS is recognized in two different clinical situations.
UnrecognizedactiveTBmaybeunmaskedearly after initiation
of highly active antiretroviral therapy (HAART) when the
development of abscesses containing acid-fast bacilli enables
diagnosis.41 Alternatively, a known TB patient on anti-TB
treatment may develop worsening of the clinical picture after
the introduction ofHAART.42 TB IRIS usually developswithin 2—
8 weeks of initiation of HAART,43 although much later pre-
sentations have been described.42 A universally accepted
clinical definition has not been established but a combination
of the development of new symptoms, new clinical signs, new
radiologicalfindings, and special investigationsmaybeneeded
to secure this diagnosis. Symptoms developing after the onset
of HAART include fever, feeling acutely unwell, and increased
cough or dyspnea. The development of new clinical signs may
involve lymph node enlargement, occurrence of skin lesions or
development of subcutaneous or muscle abscesses. Radiolo-
gical signs include new or enlarging mediastinal lymph nodes
(or abdominal nodes as seen by ultrasound or computed
tomography) and increased pulmonary infiltrates or appear-
ance of pleural effusions.41,42 An increase in the size of a
tuberculin skin test reaction, a drop in viral load and an
increase in CD4+ counts are characteristic results from special
investigations associated with IRIS.42 Further research is
needed to enable the establishment of reliable diagnostic
criteria and algorithms.
The risk for development of TB IRIS is higher in patients
receiving treatment for TB and antiretroviral treatment
simultaneously,38,39 and higher in patients with disseminated
TB.38 The immunopathology of TB IRIS is based on restoration
of mycobacteria-specific T-cells after induction of antiretro-
viral therapy. Clinical presentation of IRIS corresponds to
restoration of delayed type hypersensitivity as measured
by skin test responses to purified protein derivative
(PPD),39 and enhancement of PPD-specific Th1 cyto- and
chemokine production (IL-2, IL-12, IFN-g, CXCL10/IP-10
(IFN-g-inducible protein-10) and CXCL9/MIG (monokine
induced by g-interferon)) with no antagonizing Th2
response.44 The Th1 cytokine burst coincides with a peak
in other non-specific pro-inflammatory mediators (TNF-a, IL-
6, IL-1b, CCL5/RANTES (Regulated on Activation, Normal T-
cell Expressed and Secreted) and CCL2/MCP-1 (monocyte
chemotactic protein-1)).44,45
IRIS has not been shown to negatively influence treatment
outcome (treatment failure, increase in mycobacterial and
viral load or mortality) of HIV-infected TB patients as long as
it is managed without interrupting HIV/TB treatment.34
Identifying surrogate markers for IRIS would be clinically
useful as a confident diagnosis of this syndrome is needed
to rule out other possible etiologies, such as opportunistic
infections.
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Drug-resistant Mtb refers to isolates that withstand anti-TB
agents (any one of isoniazid, rifampin, pyrazinamide, or
ethambutol) and the term ‘multidrug-resistant’ (MDR) is
used when the isolate is resistant to at least isoniazid and
rifampin. HIV-infected persons appear to be at increased risk
for the development of drug resistance,40,46 although the
mechanisms are not clear. The pharmacokinetic interaction
between antiretroviral and anti-TB drugs that induces drug
malabsorptionmay impair treatment responses47 and lead to
acquired drug resistance40,48 and drug tolerance47 in HIV
positive TB patients. Patel et al. have advocated that clin-
icians should seriously consider introducing routine checks
of anti-mycobacterial drug levels in HIV positive TB
patients.49 The introduction of routine drug level measure-
ments in TB patients, regardless of HIV status, could poten-
tially be of great use in the fight against the development of
TB drug resistance in general, but the economic feasibility in
developing countries, where the overwhelming majority of
patients are found, is questionable. Traditional identifica-
tion of drug-resistant TB is based on failed sputum smear
conversion and on culture with drug sensitivity testing, a
time-consuming endeavor, also not readily available in
resource-limited settings. Thus, there is a need for simple,
quick and inexpensive tests to determine TB treatment
efficacy, especially in the context of HIV co-infection. One
approach could be to identify immune surrogate markers
associated with drug resistance. Recently, in the search for
such markers, Nunes et al.50 screened HIV positive TB
patients with drug-sensitive and MDR TB, with chest X-rays,
hemoglobin levels, and total lymphocyte and CD4+ counts.
No association with anti-TB drug resistance was found.
However, the search for useful markers has not been
exhausted.
Markers for TB treatment response in
HIV-infected patients
The control of active TB infection in HIV positive patients in
newly industrialized countries depends on the implementa-
tion of new treatment strategies based on existing ones
against TB and HIV individually. In order to efficiently
optimize the treatment of TB in this setting and to overcome
the problems that limit the implementation of therapy
today (what to treat first and the timing of treatment
initiation), it is crucial to identify new independent immune
signatures for each pathogen (immune correlates of Mtb
clearance or persistence and correlates of immune recon-
stitution and viral load). The identified markers could then
be integrated in a model to stratify patients on a risk scale.
Most recently, Brahmbhatt et al.51 and Veenstra et al.52
demonstrated that immune parameters could be integrated
in algorithm models for the early prediction of month 2
sputum sterilization in HIV-uninfected active TB patients. In
the light of these preliminary reports, we screened the
literature, selected and discussed some of many potential
host immunological candidate markers that could be com-
bined in such models, and investigated prospectively in a
search for predictors of TB treatment outcome in HIV
patients. For our literature search via Medline, we focusedonmarkers that have been reported within the context of TB
treatment response in HIV-infected but also HIV-uninfected
individuals (Table 1).
Currently, sputum smear status after the intensive
phase of fixed dose anti-TB drug regimens in the case of
TB,53 and CD4+ count and viral load in the case of HIV
infection, are the surrogate markers most used for asses-
sing treatment response and disease progression in these
two infections.
Mtb-specific markers
Microbiological markers: sputum smear and culture
Continuous monitoring of bacterial activity during the
course of anti-TB chemotherapy through sputum smear is
very useful in the assessment of treatment efficacy.54 How-
ever, the use of sputum status for the assessment of TB
treatment response has important limitations as a substan-
tial proportion of HIV positive TB cases have a negative
sputum smear at diagnosis.55,56 Although sputum culture
is more sensitive than smear, it can take several weeks to
obtain results of sputum cultures.57 Additionally, this is of no
benefit in HIV patients where extrapulmonary TB frequently
occurs. Cultures are also expensive and are often not avail-
able in resource constraint settings. Thus the identification
of immune correlates of TB clearance and the development
of more rapid methods for assessment of sterilization is the
challenge we face today.
Time to positivity (TTP)
With the development of culture-based TB diagnosis, a para-
meter has emerged with important potential in the assess-
ment of patient progress during therapy: time to detection
(TTD), also known as time to positivity (TTP). TTP represents
the time to detectable growth of Mtb in culture. Hanna
et al.58,59 were amongst the first to observe that TTP of
Mtb increased in samples of patients receiving anti-TB ther-
apy and that no change in TTP correlated with poor response
to therapy. Further evidence of the potential use of TTP as an
early indicator of treatment effectiveness comes from the
study by Epstein et al.60 who showed that TTP of Mtb in
sputum culture correlates with the response to anti-TB ther-
apy. Further studies are needed to investigate the value of
TTP as a biomarker of TB treatment outcome in both HIV-
infected and uninfected patients; the same disadvantages as
those of other culture methods may operate in concurrent
HIV infection.
Mtb-specific cytokine release assays for diagnosis and
response to treatment
Accurate diagnosis of TB and monitoring the efficacy of
anti-TB treatment are both crucial for the control of the TB
epidemic. Until recently, the tuberculin skin test (TST) was
the only diagnostic test for latent tuberculosis infection.
The development of new in vitro diagnostic tests such as
QuantiFERON-TB in tube (QFT-IT) and enzyme-linked immu-
nospot (ELISPOT) that are rapid, more sensitive,61,62 and
more specific for Mtb62 by minimizing cross-reactive
responses due to BCG vaccination or infection with non-
tuberculous mycobacteria,62 have surely added great
value to the diagnosis of LTBI, both in HIV negative
and non-immunocompromised HIV positive individuals.63
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Table 1 Markers of disease progression and treatment response in HIV and Mtb infection. The effect of markers discussed in this
review are summarized
Immune markers Mtb-specific value
of markera
HIV-specific
value of markerb
Associated prognosis
during therapy
(anti-TBa or ARVb)
Reference
number(s)
Microbiological and Mtb-specific markers
Positive Negative
Sputum culture/
smear after
8 weeks of
treatment
Presence of
active Mtb
— Poor response to
therapy/
poor outcomea
Good responsea 54
Increase Unchanged
TTP during
treatment
Presence of
active Mtb,
bacterial burden
— Remissiona Poor response to
therapy/poor
outcomea
58—60
Mtb-specific IFN-g
release assays
Mtb-specific
immune
competence
— Remissiona, * Poor response
to therapy/
poor outcomea, *
61—67
LTBI
Persistence/Active
disease
HIV-specific markers
Increase Decrease
CD4+ count Immune
competence
HIV infection
staging
Response to TB
treatmenta/ARVb
Poor outcomea, b 68—73
Viremia — HIV load Poor response to
therapy/poor
outcomeb
Remissionb 74,75
Non-specific host markers of inflammation
Increase Decrease
b2-Microglobulin Host inflammatory
response
Host inflammatory
response
Poor outcomea,b — 76—82
Neopterin Host inflammatory
response
Host inflammatory
response
Poor outcomea,b Remissiona,b 83—86
sTNFRII Host inflammatory
response
Host inflammatory
response
Poor outcomea,b Remissiona,b 87—91
CD8+/CD38+
T-cells
Host inflammatory
response
Host inflammatory
response
Poor outcomea,b Remission 58,92—98
suPAR Host inflammatory
response
Host inflammatory
response
Poor outcome Mtb
persistence
and predictor
of survivala, b
Remissiona,b 99—108
CXCL10/IP-10 Host inflammatory
response
Host inflammatory
response
Poor outcome Mtb
reactivationa,b
TB treatment,
ARV responsea, b
109—115
Mtb, Mycobacterium tuberculosis; ARV, antiretroviral; TTP, time to positivity; IFN-g, interferon-g; TB, tuberculosis; LTBI, latent TB
infection; sTNFRII, soluble TNF-a receptor II; suPAR, soluble urokinase plasminogen activator receptor; IP-10, IFN-g-inducible protein-10.
a Prognosis associated with TB.
b Prognosis associated with HIV.
* Subject to some controversy.Additionally, a recent study by Piana et al. reported that
the ELISPOT-based T-SPOT.TB from OxfordImmunotec (UK)
maintains its sensitivity and performance in diagnosing
latent Mtb infection in tuberculin skin test (TST) anergic
and immunocompromised individuals.64 These methods rely
on IFN-g production by T-cells in overnight whole blood
(QuantiFERON tests) or peripheral blood mononuclear cell
(PBMC) culture (ELISPOTand T-SPOT.TB) with stimulation by
Mtb-specific antigens (ESAT-6 (early secretory antigenic
target-6) and CFP-10 (culture filtrate protein-10)).Although the usefulness of these tests lies mainly in the
diagnosis of LTBI, studies have shown that these assays
could be useful to monitor the efficacy of anti-TB therapy.
However the interpretation and usefulness of these tests in
this setting remain controversial. Whereas some research-
ers have reported reduced T-cell IFN-g responses after 2—3
months of effective treatment,65,66 others have reported
an increase in IFN-g production67 and more research is
needed to define the role of these tests during concurrent
infection with HIV.
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markers for TB disease progression and
treatment response
CD4+ cell count
The CD4+ T-cell count is a valuable surrogate marker for
response to antiretroviral treatment and a risk factor for
progression of LTBI to active TB in HIV positive patients.68 It
is mainly used to establish the immunosuppressive state of
patients, for HIV treatment initiation and to monitor immune
recovery.68—70 Low baseline CD4+ counts are not only predic-
tive of the progression of asymptomatic HIV infection to AIDS
but also constitute a risk factor for opportunistic infections
suchasTB.68,71,72 Inaddition,aretrospectiveanalysisofanHIV-
infected cohort from Brazil found a mean CD4+ count of 203 in
pulmonary TB cases and 180 in patients with extrapulmonary
TB.73 Anti-TB therapy has been shown to significantly increase
CD4+ counts in both HIV positive and negative TB patients.70
Viremia
High HIV viral load is considered to be a risk factor associated
with development and progression of asymptomatic HIV infec-
tion to AIDS and infection with opportunistic pathogens, inde-
pendently of the CD4+ cell count.74,75 Low CD4+ counts with
high levels of viremia have been reported to precede the
progression to active TB in a cohort study of HIV-infected
individual in Ethiopia.68 The initiation of anti-TB treatment
in these Ethiopian subjects did not initiate a decline in viral
load, implying a poor prognosis. Viral load represents a critical
factor in the control of disease progression in HIV positive
peoplewith LTBI and shouldbeassessed independentlyofCD4+
count in order to anticipate the course of events, such as the
rate of CD4+ cell number decline, development of active TB
and progression to AIDS. However, economic realities in devel-
oping countries preclude the routine use of this test. Thus, it
has become crucial to identify correlates of HIV disease sever-
ity by more cost effective means.
Non-specific host biomarkers for TB disease
progression and response to treatment
In the following section, we will discuss candidate markers
for disease progression in HIV-infected people with LTBI or for
treatment response in active TB that have been described in
the literature. Although the measurement of some of these
markers may not currently be cost-effective in resource-poor
settings, the identification of suitable and accurate markers
would constitute a first and important step in the develop-
ment of such tests, as refinement for field site use could
achieve this goal. One problem with all these tests is that
they are not specific for TB and this may pose significant
problems for all inflammatory and immune markers in a
chronic condition that by its very nature predisposes the
host to multiple and often concurrent opportunistic infec-
tions and non-infectious complications. Nevertheless, in the
absence of specific markers, these analytes may provide
important clinical information.
b2-Microglobulin
b2-Microglobulin (b2M) is a component of the class I major
histocompatibility (MHC class I)-molecule which is present onalmost all nucleated host cells. b2M is essential for binding of
MHC class I molecules to cytosolic pathogen peptides and its
efficient transport to the cell surface for presentation to
CD8+ T-cells.76,77 b2M was one of the first immune markers to
be found elevated78 and of prognostic value79 among HIV-
infected individuals. Wanchu et al. have demonstrated that
HIV positive patients with concomitant active TB infection
have higher concentrations of b2M than HIV-infected indivi-
duals without any opportunistic infection and healthy con-
trols.80 Initiation of anti-TB therapy often results in a
significant decrease in b2M levels.80 An increase in b2M
serum levels has been associated with AIDS development
and death,81,82 and higher concentrations are found in
patients with early progression to AIDS.81
Neopterin
Neopterin is produced by activated macrophages in response
to lymphocyte-derived IFN-g.83 As enhanced levels of neop-
terin reflect the activity of cell-mediated immune responses,
its measurement in human fluids could be a useful tool for
monitoring diseases associated with the activation of cell-
mediated immune responses.84 Comparing three groups of
patients (HIV positive asymptomatic patients with and with-
out TB and HIV negative patients with TB), Immanuel et al.
demonstrated that serum neopterin was initially significantly
elevated in TB patients irrespective of their HIV status.85 In
HIV patients with active TB, neopterin levels were even
higher compared to the other two groups and inversely
correlated to CD4+ count both before and after TB treat-
ment. Even though anti-TB therapy induced a reduction in
neopterin concentration, steady high levels of neopterin in
HIV-infected or HIV/TB concurrently-infected patients were
associated with HIV disease progression and adverse out-
come.85 More recently Mildvan et al. showed that the risk
for an HIV-infected person to develop clinically active TB
could be determined six months prior to the dramatic decline
in CD4+ T-cell count and increase in viremia by measurement
of this marker.86
TNF-a and its soluble receptor II (sTNFRII)
Infection by an intracellular pathogen may induce TNF-a-
dependent apoptosis in infected cells as a defensive
mechanism by limiting the growth of intracellular patho-
gens. It has been demonstrated by Balcewicz-Sablinska
et al.87 that virulent Mtb interferes with host macrophage
apoptosis by inducing inactivation of the cytokine TNF-a
through the release of sTNFRII and formation of inactive
TNF-a—TNFRII complex. Additionally, the levels of sTNFRII
together with other soluble receptors such as sTNFRI, and IL-
1ra have been reported to be elevated in active TB patients
and down-modulated by anti-TB therapy suggesting their
potential use as markers of disease activity and in the
assessment of therapy.88 In HIV-infected patients undergoing
triple-therapy (stavudine, didanosine, and hydroxyurea),
Nokta et al.89 showed an association between sTNFRII levels
and HIV viremia. After the first week of therapy they
observed a decline in viral titer and a drop in TNF-a and
sTNFRII levels. In HIV positive patients with active TB,
increased circulating TNF-a has been linked to HIVactivity90
and its persistence during TB treatment associated with
ongoing viral replication.91
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CD38 is a glycoprotein expressed by monocytes and involved
in transduction of their activation and proliferation.58,92 The
level of CD38 expression on CD8+ T-cells has been reported to
have prognostic value for disease progression to AIDS in HIV-
infected adults and children.93—95 In children, elevated
expression of CD38 on CD8+ T-cells was found to positively
correlate with plasma viral load and to negatively correlate
with CD4+ T-cell count.93,96 Adults studies have shown that
high CD38 expression is a strong predictor of disease progres-
sion to AIDS and death.94,95 Mocroft et al. showed that a 10%
increase in CD8+/CD38+ T-cells resulted in an 88% increase in
the risk of AIDS development.97 Additionally CD8+/CD38+ T-
cell numbers have been associated with a poor response to
therapy in HIV-infected individuals.95 Increased CD38 expres-
sion on T-cells has also been reported in active TB patients
and has been shown to return to baseline after successful
anti-TB chemotherapy.98 These findings point to CD38 as a
candidate biomarker for the progression of disease and for
treatment response in concurrent HIV/TB infection. How-
ever, studies of differential CD38 expression profiles in peo-
ple with different TB and HIV infection status are needed to
develop clinically useful approaches using this marker.
Soluble urokinase plasminogen activator receptor
(suPAR)
Different cell types, including neutrophils, phagocytes, acti-
vated T-cells, endothelial cells and tumor cells, express the
urokinase plasminogen activator receptor (uPAR).99 uPAR,
like the soluble form of the receptor, suPAR, is a flexible
molecule,100 enabling it to interact with several ligands and
engage in numerous immunological activities including che-
mokinesis, cell migration, differentiation, chemokine recep-
tor regulation, and plasminogen activation.101
In recent years, it has become evident that elevated suPAR
levels are prognostic of a poor outcome in infectious diseases
including malaria,102 pneumococcal pneumonia,103 strepto-
coccal infection,104 active TB105 and HIV.106 The prognostic
value of suPAR in HIV-1 infection is similar in strength to, and
independent of, CD4+ count and viral load.106 The uPAR ligand,
urokinase, mediates a negative signal on the late stages of the
HIV-1 lifecycle in vitro throughbinding to cell-bound uPAR, and
the scavenging of urokinase by suPAR may partly explain the
strong prognostic value of suPAR in HIV-infection.107 There is
strong support of suPAR as a marker in HIV infection.106,108
Ostrowski et al.106 and Sidenius et al.108 showed that plasma
concentrations of different forms of suPAR are positively
associated with immune activation and independent predic-
tors ofmortality in HIV patients. As suPAR significantly predicts
CD4+ T-cell decline (unpublished observation), combined
suPAR and CD4+ T-cell count measurement in HIV-infected
individuals can aid in clinical decisions on when to test viral
load and when to initiate antiretroviral therapy. However, the
lack of a commercially available assay allowing comparisons of
data from at different study sites hampers the comprehensive
evaluation of the prognostic potential of this marker and the
effects of race and co-infection on expression levels. Several
studies are now ongoing using the suPARnostic assay (launched
August 2006), which has been developed for clinical use in HIV-
1 infection. These studies will determine whether suPAR is a
serious candidate marker for disease progression in HIV, TB,
and co-infected patients.CXCL10/IP-10
IFN-g-inducible protein-10 (IP-10 or CXCL10) is an activated
T-cell and monocyte chemotactic factor involved in delayed-
type hypersensitivity.109 CXCL10 has been found in vivo in
lymph nodes and in lung tuberculous granulomas.110
Studies have correlated serum CXCL10 levels with TB
infection; serum levels of CXCL10 were higher in patients
with active TB than in household and community controls at
diagnosis ( p < 0.0001), and increased after reactivation of a
latent infection.111 Others have found elevated CXCL10 con-
centrations during active TB, with higher levels in patients
with fever and anorexia.112 CXCL10 also has potential as a
marker for TB treatment efficacy. Cured patients showed
significant reductions in serum CXCL-10 at two months and at
the end of treatment ( p < 0.0001) in one study, whereas non-
cured patients showed no reduction in CXCL10 levels.111
CXCL10 is induced by HIV in vitro,113 and both sympto-
matic and asymptomatic HIV patients have been found to
have elevated plasma levels of this marker. HAART has been
shown to induce a significant decrease in plasma levels of
CXCL10, which correlate negatively with CD4+ T-cell
counts.114,115 In a population of patients with active TB,
serum CXCL10 levels were higher in HIV positive patients
than in HIV negative patients.112
Biomarkers –— beyond disease progression
and prognosis
Reliable biomarkers for different TB disease states would
contribute significantly to clinical management and to clin-
ical trials of new TB drugs. Markers for progression to active
TB in latently infected HIV positive individuals would allow
timely interventions. Additionally, the current clinical man-
agement of TB treatment, where the response to therapy in
individuals is monitored by sputum smear conversion after 8
and 26 weeks of treatment, would certainly benefit from
appropriate biomarkers that are measured early during the
course of treatment, especially in the context of concurrent
HIV infection. Identification of patients with a high risk for
poor outcome before the start of treatment or during early
treatment would allow the health care system to focus their
resources on increased surveillance of such high-risk patients
and possibly on intensified treatment regimens.
The efficacy of TB treatment regimes is currently assessed
by recurrence rates within 2 or 5 years of treatment comple-
tion and this is not conducive to the development of new TB
drugs. Trials simply take too long and are therefore too costly
in a market with challenging profit margins. Surrogate mar-
kers for treatment response would allow the early identifica-
tion of ineffective drugs and would therefore shorten the
duration of trials. This is of particular importance as at least
90% of new drugs entering clinical testing fail to reach the
markets.116
Clearly, the potential markers discussed above still fall far
short of clinically valuable indicators of disease progression,
individual treatment responses or treatment regimen effica-
cies, as they lack both sensitivity and specificity. More
research emphasis needs to be put on the development of
surrogate markers of treatment response. In our attempts to
find useful surrogate markers for evaluation in people with
differential outcomes of infection and treatment we often
296 J.F. Djoba Siawaya et al.rely on our limited understanding of the nature of protective
responses. It is however likely that better markers do exist
that have escaped our attention, and new technologies
should be applied more extensively in this field. New multi-
plex assays, such as the Luminex X-map technology, which
enables the simultaneous measurement of up to 200 plasma
proteins, may become important tools in the ongoing search
for biomarkers. Proteomic,117 metabonomic118 and differen-
tial gene expression analysis have opened the door to the
discovery of hitherto unknown markers of disease out-
comes.119,120 Additionally, the use of weighted algorithms
and calculated risk scores should be investigated and these
could include combinations of markers rather that an over-
optimistic reliance on single analytes to predict a particular
clinical course.
In conclusion, there are currently no reliable single sur-
rogatemarkers for disease progression or treatment response
although combinations of known markers have not been
sufficiently evaluated. The first challenge in this field is to
find new markers for inclusion into such predictive models,
but an equally challenging task will be the development of
new detection methods that will enable measurement of
these markers on a large scale in resource-poor settings.
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